Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program
The BPDCN International Registry Program provides a valuable tool in consolidating global data and fostering collaboration among researchers and clinicians. This collaborative effort involving multiple countries on several continents not only aims to advance our comprehension of BPDCN but also lays the groundwork for standardized treatment protocols for improving outcomes for BPDCN patients worldwide.
Authors
- Sameer Bakhshi (ORCID: https://orcid.org/0000-0001-9367-4407)
- Nerses Ghahramanyan (ORCID: https://orcid.org/0000-0002-3661-0009)
- Karen Bedirian (ORCID: https://orcid.org/0000-0003-1582-8073)
- Shushan Hovsepyan (ORCID: https://orcid.org/0000-0002-7367-6752)
- Rejin Kebudi (ORCID: https://orcid.org/0000-0003-4344-8174)
- Funda Tekkeşin (ORCID: https://orcid.org/0000-0002-0487-5643)
- Gevorg Tamamyan (ORCID: https://orcid.org/0000-0002-2740-9215)
- Shaimaa El‐Ashwah (ORCID: https://orcid.org/0000-0003-2210-1534)
- Salma Elashwah (ORCID: https://orcid.org/0000-0003-2919-9263)
- Ruzanna Papyan (ORCID: https://orcid.org/0000-0003-1949-6280)
- Samvel Bardakhchyan (ORCID: https://orcid.org/0000-0002-5767-6373)
- Maria Badikyan
- Dickran Gano Kazandjian (ORCID: https://orcid.org/0000-0002-6593-0917)
- Nare Martirosyan
- Michalis Michael (ORCID: https://orcid.org/0000-0003-3160-4870)
- Enrico Attardi (ORCID: https://orcid.org/0009-0008-4801-5048)
- Carolyn Owen (ORCID: https://orcid.org/0000-0003-4110-1708)
- Nino Totogashvili
- Maria Teresa Voso (ORCID: https://orcid.org/0000-0002-6164-4761)
- Robin Ohannessian (ORCID: https://orcid.org/0000-0003-1999-7683)
- M. Tezer Kutluk (ORCID: https://orcid.org/0000-0002-1918-4407)
- Pavel P Kotoucek
- Mazin Faisal Al‐Jadiry (ORCID: https://orcid.org/0000-0003-3773-9135)
- Arusyak Ivanyan
- Consolato Maria Sergi (ORCID: https://orcid.org/0000-0002-2779-7879)
- Deniz Tuğcu (ORCID: https://orcid.org/0000-0002-4374-7134)
- Ahmad Alhuraiji (ORCID: https://orcid.org/0000-0002-4669-0233)
- Min‐Yu Su (ORCID: https://orcid.org/0000-0002-7478-7067)
- Alvaro Jose Alencar (ORCID: https://orcid.org/0000-0002-1720-9295)
- Naveen Pemmaraju (ORCID: https://orcid.org/0000-0002-1670-6513)
- Justin Taylor (ORCID: https://orcid.org/0000-0003-4407-6325)
- Maria Paola Martelli (ORCID: https://orcid.org/0000-0001-9139-1729)
- Mariam Abramashvili
- Samvel Danelyan
- Ching‐Tien Peng
- Hasanein H. Ghali (ORCID: https://orcid.org/0000-0003-0860-1479)
- Marina Konopleva
- Astghik Voskanyan (ORCID: https://orcid.org/0000-0002-6949-506X)
- Vassilios Lazaris
Institutions
- University of Rome Tor Vergata (IT)
- Albert Einstein College of Medicine (US)
- A. Alikhanyan National Laboratory (AM)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- University of Ottawa (CA)
- Mansoura University (EG)
- University of Calgary (CA)
- China Medical University (TW)
- Yerevan State University (AM)
- Children's Hospital of Eastern Ontario (CA)
- Baghdad Medical City (IQ)
- Central State Hospital (US)
- Nicosia General Hospital (CY)
- Telemedicine & Advanced Technology Research Center (US)
- Broomfield Hospital (GB)
- Kuwait Cancer Control Center (KW)
- Azienda Ospedaliera di Perugia (IT)
- Ümraniye Eğitim ve Araştırma Hastanesi (TR)
- China Medical University Hospital (TW)
- Sağlık Bilimleri Üniversitesi (TR)
- Center of Medical Genetics and Primary Health Care (AM)
- Sylvester Comprehensive Cancer Center (US)
- DR. B.R.A. Institute Rotary Cancer Hospital (IN)
- Cyprus College (CY)
- Yerevan State Medical University (AM)
- Istanbul University (TR)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1007/s12672-025-02433-2
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Amgen
- Eli Lilly and Company
- Astellas Pharma US
- AstraZeneca
- Gilead Sciences
- American Society of Clinical Oncology
- Celgene
- F. Hoffmann-La Roche
- MEI Pharma
- BeiGene
- Incyte
- Astellas Pharma
- Aptitude Health
- National Institutes of Health
- Genentech
- National Cancer Institute